Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mariam Allbee-Johnson

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Blood Advances|August 30, 2021
Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioningJohn E Wagner, Karen K Ballen, Mei-Jie Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2024
The health risk of social disadvantage is transplantable into a new hostLucie M Turcotte, Tao Wang, Kirsten M Beyer, et al.
Transplantation and Cellular Therapy|June 13, 2024
Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient OutcomesYung-Tsi Bolon, Rasha Atshan, Mariam Allbee-Johnson, et al.
Transplantation and Cellular Therapy|January 4, 2025
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisCindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, et al.
Transplantation and Cellular Therapy|November 14, 2021
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial OutcomesPaul V O'Donnell, Claudio G Brunstein, Ephraim J Fuchs, et al.
British Journal of Haematology|March 14, 2022
Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?Mouhamed Yazan Abou-Ismail, Raphael Fraser, Mariam Allbee-Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2026
Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell TransplantNicole Liberio, Mariam Allbee-Johnson, Kwang Woo Ahn, et al.
Transplantation and Cellular Therapy|September 10, 2021
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid MalignancyNina Orfali, Mei-Jie Zhang, Mariam Allbee-Johnson, et al.
Transplantation and Cellular Therapy|March 22, 2022
Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell TransplantationSagar S Patel, Kwang Woo Ahn, Manoj Khanal, et al.
Transplantation and Cellular Therapy|June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research RegistryRachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Blood Advances|August 30, 2021
Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioningJohn E Wagner, Karen K Ballen, Mei-Jie Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2024
The health risk of social disadvantage is transplantable into a new hostLucie M Turcotte, Tao Wang, Kirsten M Beyer, et al.
Transplantation and Cellular Therapy|June 13, 2024
Leveraging Hematopoietic Cell Transplant Data and Biorepository Resources at the Center for International Blood and Marrow Transplant Research to Improve Patient OutcomesYung-Tsi Bolon, Rasha Atshan, Mariam Allbee-Johnson, et al.
Transplantation and Cellular Therapy|January 4, 2025
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease ProphylaxisCindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, et al.
Transplantation and Cellular Therapy|November 14, 2021
Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial OutcomesPaul V O'Donnell, Claudio G Brunstein, Ephraim J Fuchs, et al.
British Journal of Haematology|March 14, 2022
Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?Mouhamed Yazan Abou-Ismail, Raphael Fraser, Mariam Allbee-Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2026
Optimizing Haploidentical Donor Selection for Pediatric Hematopoietic Cell TransplantNicole Liberio, Mariam Allbee-Johnson, Kwang Woo Ahn, et al.
Transplantation and Cellular Therapy|September 10, 2021
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid MalignancyNina Orfali, Mei-Jie Zhang, Mariam Allbee-Johnson, et al.
Transplantation and Cellular Therapy|March 22, 2022
Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell TransplantationSagar S Patel, Kwang Woo Ahn, Manoj Khanal, et al.
Transplantation and Cellular Therapy|June 29, 2024
Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research RegistryRachel Cusatis, Carlos Litovich, Zhongyu Feng, et al.
Pageof 1